Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Accumulated Expenses (2016 - 2021)

Assembly Biosciences (ASMB) has 7 years of Accumulated Expenses data on record, last reported at $3.7 million in Q3 2021.

  • For Q3 2021, Accumulated Expenses fell 15.88% year-over-year to $3.7 million; the TTM value through Sep 2021 reached $3.7 million, down 15.88%, while the annual FY2020 figure was $4.4 million, 7.92% down from the prior year.
  • Accumulated Expenses reached $3.7 million in Q3 2021 per ASMB's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $10.1 million in Q1 2019 and bottomed at $2.8 million in Q2 2019.
  • Average Accumulated Expenses over 5 years is $5.2 million, with a median of $4.5 million recorded in 2020.
  • Peak YoY movement for Accumulated Expenses: surged 222.84% in 2017, then crashed 54.31% in 2020.
  • A 5-year view of Accumulated Expenses shows it stood at $6.4 million in 2017, then decreased by 26.84% to $4.6 million in 2018, then increased by 3.84% to $4.8 million in 2019, then decreased by 7.92% to $4.4 million in 2020, then dropped by 15.75% to $3.7 million in 2021.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $3.7 million in Q3 2021, $3.7 million in Q2 2021, and $4.3 million in Q1 2021.